{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021130","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.727949+00:00","generated_at":"2026-06-05T11:54:00.773270+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"REGENXBIO reports Q4 net loss $62.9M, cash $314M; pipeline milestones for 2024","bullets":["Q4 net loss $62.9M ($1.43/sh); full year net loss $263.5M ($6.02/sh); 2023 revenue $90.2M vs $112.7M in 2022.","Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2023; expected to fund operations into H2 2025.","ABBV-RGX-314 wet AMD subretinal pivotal trials on track for global submissions late 2025-early 2026; suprachoroidal data mid-2024.","RGX-202 Duchenne pivotal dose determination mid-2024; RGX-121 MPS II BLA filing planned for 2024 via accelerated approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021130","json":"https://secwatch.observer/filing/0000950170-24-021130.json","markdown":"https://secwatch.observer/filing/0000950170-24-021130.md","text":"https://secwatch.observer/filing/0000950170-24-021130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024021130/0000950170-24-021130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024021130/rgnx-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:54:00.773270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}